Clinical Trial Update: A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating VI-0521 on psychomotor performance in healthy overweight and obese adults has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• VI-0521

Snippet

Sponsor: VIVUS LLC | Conditions: Overweight, Obesity | Phase 2 | Status: COMPLETED | Results posted: 2013-09-13